Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More
Exalpha Biologicals, Inc.

Influenza A, H1N1 New Caledonia 20/99, Hemagglutinin, Recombinant (Full Length)

  • Product Code: X2565
  • Size: 10 µg
  • Availability: In Stock In Stock
  • Price (USD): $388

Cat #

X2565		 Quantity:      

Data Sheet

Product Name

Influenza A, H1N1 New Caledonia 20/99, Hemagglutinin, Recombinant (Full Length)

Host/Source

Sf9 cells

Product Type

Recombinant Protein

Applications

Elisa, WB

Purification

≥ 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin:

Size

10 µg

Price (USD)

$388

Background

Influenza virus is a single-stranded RNA virus, segmented, 70nm in diameter and enveloped. Strains are described by geographic origin, strain number, year of isolation and hemagglutination (H) and neuraminidase (N) antigens.

Immunogen

Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 72kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

Positive Control

Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 7.5kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

Formulation

Supplied as a sterile solution in 10mM sodium phosphate, pH 7.2, 150mM sodium chloride.

Customer Storage

May be stored at 4

Target Molecular Weight

72 kDa

References

1. Wrammert, J., et al. ?Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.? J. of Exp. Med. (2011), 208, 181-193.